Fully Human B7H3 CAR-T Cells Therapy

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameFully Human B7H3 CAR-T Cells Therapy
Drug Alias NameFully Human B7H3 CAR-TfhB7H3.CAR-Ts
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionCD276 antigen inhibitorsT lymphocyte replacements
TargetsCD276 antigen
Therapy Area/IndicationsOvarian NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThe Affiliated Hospital Of Xuzhou Medical University
China Registration ClassN/A

Develop Information

Active CompaniesThe Affiliated Hospital Of Xuzhou Medical UniversityXuzhou Medical University (Xzmu)
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A